

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## **COMPLETION OF DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF TRADEMARKS**

References are made to the announcement of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) dated 27 December 2018 and the circular of the Company dated 31 January 2019 in relation to, among others, the acquisition of the Target Trademarks (being the WangLaoJi\* series trademarks). Capitalised terms used in this announcement have the same meanings as defined in the said circular unless the context otherwise requires.

The Company is pleased to announce that all the conditions precedent to the Acquisition as set out in the Trademark Acquisition Agreement have been satisfied and Completion took place on 30 April 2019. In accordance with the Trademark Acquisition Agreement, the Company and GPLH entered into the Completion Confirmation on the same day to facilitate the transfer of the Target Trademarks.

The Board of

**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 30 April 2019

*As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong, Mr. Li Hong and Mr. Wu Changhai as executive directors, and Mr. Chu Xiaoping, Mr. Jiang Wenqi, Mr. Wong Hin Wing and Ms. Wang Weihong as independent non-executive directors.*